ArticleWorld journal of diabetes2025
Autologous platelet rich gel in treatment of lower limb atherosclerotic occlusive disease in diabetic patients.
Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Gel Technologies for Atherosclerosis Research and Intervention.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower limb atherosclerotic occlusive disease (LAOD) is a common complication in diabetic patients, leading to significant symptoms and reduced quality of life.
aimTo investigate the efficacy of autologous platelet-rich gel (APRG) as an innovative treatment for LAOD, focusing on clinical outcomes such as symptom relief, flow values, ankle-brachial index (ABI), walking distance, and claudication severity.
methodsThis retrospective study involved an analysis of electronic medical records (EMR) from 150 patients diagnosed with LAOD. Participants were assigned to either a treatment group (
resultsThe APRG group showed significant improvements after 12 weeks, including a 70% reduction in pain, a 65% increase in wound healing rates, and an average walking distance increase of 150 meters. Flow values improved by 20%, with significant enhancements in ABI measurements (
conclusionThe APRG demonstrates significant efficacy in managing LAOD in diabetic patients, improving key clinical parameters including flow values, ABI, walking distance, and claudication. These findings support the need for further prospective studies to validate long-term efficacy and optimize treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.